Brown, Michael C. http://orcid.org/0000-0002-3957-1164
Mosaheb, Mubeen M.
Mohme, Malte
McKay, Zachary P.
Holl, Eda K.
Kastan, Jonathan P.
Yang, Yuanfan http://orcid.org/0000-0003-1581-451X
Beasley, Georgia M.
Hwang, E. Shelley
Ashley, David M.
Bigner, Darell D.
Nair, Smita K. http://orcid.org/0000-0001-7019-1912
Gromeier, Matthias http://orcid.org/0000-0003-4538-0302
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (R01 NS108773)
U.S. Department of Defense (W81XWH-16-1-0354)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (F32 CA224593, R35 CA225622)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 22 May 2020
Accepted: 24 February 2021
First Online: 25 March 2021
Competing interests
: M.C.B., D.D.B., D.M.A., S.K.N., and M.G. own intellectual property related to this research, which has been licensed to Istari Oncology, Inc. M.G. and D.D.B. are compensated advisors to- and own equity in Istari Oncology, Inc. S.K.N., M.C.B., D.D.B., and M.G. are inventors on patent application PCT/US2017/039953 held/submitted by Duke University that covers the composition and methods for activating antigen-presenting cells with PVSRIPO. All other authors declare no competing interests.